JP#WUXI RP2812A.P (61915) News

Wuxi Biologics (Cayman) Stock Advances 3.5% in Hong Kong

Dow Jones16:31

Guosheng Securities: The rebound trend in the pharmaceutical and biotechnology sector is confirmed; favorable views on the innovative drug industry chain and healthcare technology.

The field of brain-computer interfaces has progressed from exploratory frontier technology to a framework supported by national industrial policy.

Zhitong Finance16:19

In the first half of the year, outbound licensing deals for innovative drugs from China exceeded USD 100 billion, reaching a new record high.

Tao Qing, Director of the Bureau of Operation Monitoring and Coordination at the Ministry of Industry and Information Technology, stated this morning (20th) at a press conference held by the State Council Information Office that China has seen a steady stream of high-quality innovative pharmaceutical achievements in the first half of this year, with 38 innovative drugs approved for market launch—31 of which are domestically developed. Out-licensing deals for innovative drugs have reached a record high, with total transaction value exceeding USD 100 billion. Tao noted that despite a complex and challenging external environment and industry transformation pressures, China’s pharmaceutical industry has demonstrated remarkable resilience. In the first half of the year, the value-added output of designated-size pharmaceutical enterprises grew by 6.4% year-on-year, with biological products recording double-digit growth and emerging as the primary driver accelerating industry development.

AASTOCKS13:52

Latest holdings of products under E Fund Management disclosed: Fu Pengbo initiated a position in Focuslight Technologies, while Zhao Feng bought back Wuxi Bio.

Gelonghui, July 17 | On July 17, the second-quarter 2026 reports of funds managed by two star fund managers at E Fund disclosed their latest top ten holdings. During the second quarter of 2026, the E Fund Growth Value Mixed Fund, co-managed by Fu Pengbo and Zhu Lin, reduced its Hong Kong equity allocation to a historic low. In terms of portfolio adjustments, the fund initiated a new position in Focuslight Technologies and significantly reduced holdings in Zhongji Xuchuang and Dongshan Precision. Meanwhile, the E Fund Balanced Value Three-Year Holding Fund, managed by another star fund manager Zhao Feng, repurchased Wuxi Bio after a one-year absence and increased its stakes in ZTO Express and China Resources Land.

Gelonghui FinanceJul 17 19:58

Wuxi Biologics (Cayman) Stock Slips 6.0% in Hong Kong

Dow JonesJul 17 16:30

Policy, industry, and capital converge: a critical window emerges for innovative drugs

Amid the confluence of multiple positive factors, the long-term growth thesis for innovative pharmaceuticals continues to strengthen, with rising certainty in valuation recovery and earnings realization in the second half of the year, further bolstering market confidence in the sector’s long-term growth prospects.

Zhitong FinanceJul 17 07:06

Wuxi Bio (02269.HK): Innovation Drives Rapid Business Growth; Bispecific and Multispecific Antibodies Expected to Become Key Growth Engine

Newly signed projects continue to grow, and the pipeline funnel effect is evident, providing certainty for the company’s sustained business growth: leveraging its industry-leading technological advantages, exceptional team execution capabilities, and continuously deepening global footprint, the company continues to secure a substantial volume of newly signed projects,

SDIC SecuritiesJul 16 16:57

Hong Kong Stock Market Concept Tracker | Experimental Monkey Prices Soar to RMB 200,000! Multiple Companies Report Severe Shortages as CRO Sector Orders Rebound Broadly (Including Related Stocks)

Recently, with increased activity in new drug development, laboratory monkeys have once again become scarce, driving their price up to RMB 200,000 per animal.

Zhitong FinanceJul 16 07:49

Accelerated partnerships and influx of industry giants propel AI-driven drug discovery into commercial fast lane

A Goldman Sachs research report indicates that AI can shorten drug time-to-market by approximately 20% to 25%, reduce the R&D process by about three years, and potentially lower overall development costs by roughly 25% to 30%.

Zhitong FinanceJul 16 07:08

Dual catalysts of innovative drugs going global and accelerated policy support drive strong gains across Hong Kong-listed biotech stocks, with Zhaoyan New Drug surging nearly 22%.

① What is the pass rate for the formal review of innovative drugs under the National Reimbursement Drug List (NRDL) and commercial insurance in 2026? ② How have outbound licensing deals for China’s innovative drugs performed in the first half of this year?

cls.cnJul 15 11:30

Wuxi Biologics (Cayman) Stock Advances 2.4% in Hong Kong

Dow JonesJul 14 16:31

《Major Brokerage》UBS Group: China's CRO industry posted solid revenue growth in the first half; names Wuxi Apptec (02359.HK) as top pick

UBS Group published a research report stating that a number of CDMO pharmaceutical companies will release their first-half earnings. Benefiting from robust demand for novel drug modalities and steady order momentum, their interim performance is expected to remain strong, supporting the firm's view that the sector will continue to outperform the broader market. The report forecasts strong second-quarter TIDES revenue growth for Wuxi Apptec (02359.HK), with full-year guidance pointing to approximately 40% year-over-year growth. Small-molecule business remains resilient, driven by GLP-1 and other new drugs, while the impact from the 1260H bill is expected to be limited. UBS has slightly raised its revenue forecasts for Wuxi Apptec for 2026–2028 and increased its net profit forecast by 0.5%, raising the target price from HK$171.

AASTOCKSJul 14 15:11

Major Brokerage: UBS Group's Investment Rating and Target Price for CRO Shares (Table)

UBS Group published a research report listing the investment ratings and target prices for CRO shares as follows: Stock | Investment Rating | Target Price (HKD) Wuxi Apptec (02359.HK) | Buy | HK$171.2 → HK$176.5 Wuxi Bio (02269.HK) | Buy | HK$51.1 Wuxi XDC (02268.HK) | Buy | HK$89.4 → HK$87.4 Pharmaron (03759.HK) | Buy | HK$30 → HK$31.8 Tigermed (03347.HK) | Buy |

AASTOCKSJul 14 14:49

In the first half of the year, China's total outbound licensing deals for innovative drugs reached USD 110 billion, hitting a new record high.

Reporters from China Central Television (CCTV) learned today (the 13th) from the National Medical Products Administration that from January to June this year, the total value of outbound licensing deals for Chinese innovative drugs reached approximately USD 110 billion—equivalent to 80% of the full-year total for 2025—setting a new historical record. According to the latest statistics, as of June 30, there were 81 outbound licensing transactions involving Chinese innovative drugs, with a combined transaction value of approximately USD 110 billion, amounting to 80% of the projected total for all of 2025. The data further indicate that during the first half of this year, these outbound licensing deals spanned ten therapeutic areas, including oncology, metabolic diseases, immunology, and neurology, with the primary licensees based in the United States, the United Kingdom, France, and Italy.

AASTOCKSJul 13 17:20

Multiple positive catalysts lifted pharmaceutical stocks, with institutional analysts confirming a right-side reversal in the CXO sector's sentiment.

Biotech stocks listed in Hong Kong extended their gains. As of the time of writing, Pregene Biopharma surged over 38%, Joinn Laboratories rose more than 15%, Biointron climbed nearly 14%, Duality Biologics gained over 11%, PharmAgra Labs advanced over 8%, and Tigermed increased by nearly 8%.

cls.cnJul 10 11:12

WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

PR NewswireJul 9 15:31

Hong Kong Market Midday Commentary | Hang Seng Index Down 0.78% in Morning Session; Semiconductors Rise Against the Trend

Most semiconductor stocks rose. Changxin Technology's IPO is imminent, as strong domestic computing power demand gradually materializes.

Zhitong FinanceJul 9 12:00

Hong Kong Stock Market Update | Wuxi Bio (2269.HK) rises over 6% in early trading as its MFG8 drug substance manufacturing facility passes the U.S. FDA pre-approval inspection

Wuxi Bio (02269) rose more than 6% in early trading. As of the time of writing, it was up 4.6% at HK$37.3, with a trading volume of HK$445 million.

Zhitong FinanceJul 9 10:13

Express News | Wuxi Bio's MFG8 Drug Substance Manufacturing Facility Passes U.S. FDA Pre-License Inspection

BreakingsJul 9 09:13

WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year

PR NewswireJul 8 15:15